Search research articles
Contact Us
Filters
Showing results (51-60 of 81) with videos related to
Page
of 9
Sort By:
Therapeutic Advances in Medical Oncology
|
December 7, 2020
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer
Ulrike Nitz, Oleg Gluz, Hans H Kreipe, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 6, 2022
Ten years of live surgical broadcast at Charité-MAYO conferences (2010-2019): a systematic evaluation of the surgical outcome
Judith Altmann, Radoslav Chekerov, Christina Fotopoulou, et al.
JAMA Surgery
|
June 7, 2023
Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer
Sherko Kuemmel, Joerg Heil, Simona Bruzas, et al.
Annals of Surgery
|
November 6, 2020
A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients
Sherko Kuemmel, Joerg Heil, Anna Rueland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2022
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial
Oleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, et al.
Annals of Surgery
|
July 14, 2020
Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03
Joerg Heil, André Pfob, Hans-Peter Sinn, et al.
Journal of the National Cancer Institute
|
December 12, 2017
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results
Oleg Gluz, Ulrike Nitz, Cornelia Liedtke, et al.
The Journal of Clinical Investigation
|
July 24, 2025
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and non-responders
Guokun Zhang, Vindi Jurinovic, Stephan Bartels, et al.
JAMA Network Open
|
February 26, 2025
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
Lisa Richters, Oleg Gluz, Nana Weber-Lassalle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2022
Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery
André Pfob, Chris Sidey-Gibbons, Geraldine Rauch, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 81) with videos related to
Sort By:
Page
of 9
Therapeutic Advances in Medical Oncology
|
December 7, 2020
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer
Ulrike Nitz, Oleg Gluz, Hans H Kreipe, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 6, 2022
Ten years of live surgical broadcast at Charité-MAYO conferences (2010-2019): a systematic evaluation of the surgical outcome
Judith Altmann, Radoslav Chekerov, Christina Fotopoulou, et al.
JAMA Surgery
|
June 7, 2023
Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer
Sherko Kuemmel, Joerg Heil, Simona Bruzas, et al.
Annals of Surgery
|
November 6, 2020
A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients
Sherko Kuemmel, Joerg Heil, Anna Rueland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2022
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial
Oleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, et al.
Annals of Surgery
|
July 14, 2020
Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03
Joerg Heil, André Pfob, Hans-Peter Sinn, et al.
Journal of the National Cancer Institute
|
December 12, 2017
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results
Oleg Gluz, Ulrike Nitz, Cornelia Liedtke, et al.
The Journal of Clinical Investigation
|
July 24, 2025
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and non-responders
Guokun Zhang, Vindi Jurinovic, Stephan Bartels, et al.
JAMA Network Open
|
February 26, 2025
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
Lisa Richters, Oleg Gluz, Nana Weber-Lassalle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2022
Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery
André Pfob, Chris Sidey-Gibbons, Geraldine Rauch, et al.
Page
of 9